What does UNIZIMA do?

UNIZIMA is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Public Limited, started on 2 March 2020, 3 establishments.

What is the address of UNIZIMA?

The registered office of UNIZIMA is located at Zoning de Jumet,avenue Centrale 52, 6040 Charleroi.

Is UNIZIMA still active?

No. The CBE lists UNIZIMA with legal situation “Opening faillissement”. The date of the court ruling is published in the Belgian Official Gazette; the register does not carry it.

Is UNIZIMA registered on Peppol?

No, UNIZIMA is currently not registered on the Peppol network.

What is the enterprise number of UNIZIMA?

The enterprise number of UNIZIMA is BE0744643759.

When was UNIZIMA founded?

UNIZIMA was founded on 2 March 2020.

Who are the directors of UNIZIMA?

According to the 2023 annual accounts, the directors of UNIZIMA are: Hugues BULTOT, Viva Finance SRL, Alerion BV, José CASTILLO.

Is UNIZIMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Opening faillissement according to the CBE, started on 2 March 2020; 3 annual accounts filed, latest fiscal year 2023; 4 directors known from the annual account; 3 establishments in the CBE.

How much profit did UNIZIMA make in 2023?

UNIZIMA recorded a loss after taxes of € 3,032,542 in financial year 2023.

What is the revenue of UNIZIMA?

In its most recent annual accounts (2023), UNIZIMA reported revenue of € 1,816,295.

How much does an employee at UNIZIMA earn?

The average wage cost per full-time employee at UNIZIMA was € 151,900 in 2023: staff costs of € 1.2 million for 8.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does UNIZIMA have?

According to the 2023 annual accounts, UNIZIMA has 8.2 full-time equivalents (FTE).

UNIZIMA (Public Limited) - Charleroi - BE0744643759

Dossier UNIZIMA, printed on 29 October 2026 from databakkes.be/en/0744643759/unizima. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2022 and 2023.
Legal situation KBO

Opening faillissement according to the CBE.

Financials

Financial year 2023

UNIZIMA from Charleroi, company number BE0744643759, closed financial year 2023 with a result of € -3 million after tax. For that financial year UNIZIMA recorded revenue of € 1.8 million and equity of € 5.3 million. Compared with financial year 2022, the result moved from € -4.7 million to € -3 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2024.

What it is worth Growing

€ 5.3 million

▲ 102% vs 2022

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3 million

▲ 36 % less loss than in 2022

Profit after tax over the fiscal year.

Cash in the bank

€ 715,992

▼ 80% vs 2022

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1.9 million.

People and assets in 2023

Full-time equivalents

8.2

▼ 3.9 vs 2022

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 1.3 million in 2023, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.2 million

▼ 19% vs 2022

€ 151,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2023

Bank debt

€ 712

▼ 91% vs 2022

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 854,780

▼ 34% vs 2022

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 127 days on average.

Taxes and wages

€ 126,110

▼ 65% vs 2022

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	Change 2022 → 2023
Revenue	€ 366,560 Revenue 2021: € 366,560 First fiscal year in the series	€ 925,941 Revenue 2022: € 925,941 ▲ 153% vs 2021 (€ 366,560) Favourable step	€ 1,816,295 Revenue 2023: € 1,816,295 ▲ 96% vs 2022 (€ 925,941) Favourable step	▲ 96%
Profit after taxes	€ -1,898,641 Profit after taxes 2021: € -1,898,641 First fiscal year in the series	€ -4,718,440 Profit after taxes 2022: € -4,718,440 ▼ € 2.8 million vs 2021 (€ -1,898,641) Unfavourable step	€ -3,032,542 Profit after taxes 2023: € -3,032,542 ▲ € 1.7 million vs 2022 (€ -4,718,440) Favourable step	▲ € 1.7 million
Equity	€ 1,757,168 Equity 2021: € 1,757,168 First fiscal year in the series	€ 2,622,371 Equity 2022: € 2,622,371 ▲ 49% vs 2021 (€ 1,757,168) Favourable step	€ 5,302,074 Equity 2023: € 5,302,074 ▲ 102% vs 2022 (€ 2,622,371) Favourable step	▲ 102%
Total debts	€ 1,129,081 Total debts 2021: € 1,129,081 First fiscal year in the series	€ 2,383,848 Total debts 2022: € 2,383,848 ▲ 111% vs 2021 (€ 1,129,081) Unfavourable step	€ 1,934,264 Total debts 2023: € 1,934,264 ▼ 19% vs 2022 (€ 2,383,848) Favourable step	▼ 19%
Cash	€ 229,881 Cash 2021: € 229,881 First fiscal year in the series	€ 3,596,893 Cash 2022: € 3,596,893 ▲ € 3.4 million vs 2021 (€ 229,881) Favourable step	€ 715,992 Cash 2023: € 715,992 ▼ 80% vs 2022 (€ 3,596,893) Unfavourable step	▼ 80%
Retained profit	€ -2,007,348 Retained profit 2021: € -2,007,348 First fiscal year in the series	€ -3,447,336 Retained profit 2022: € -3,447,336 ▼ € 1.4 million vs 2021 (€ -2,007,348) Unfavourable step	€ -1,904,395 Retained profit 2023: € -1,904,395 ▲ € 1.5 million vs 2022 (€ -3,447,336) Favourable step	▲ € 1.5 million
Bank debt	€ 712 Bank debt 2021: € 712 First fiscal year in the series	€ 7,712 Bank debt 2022: € 7,712 ▲ € 7,000 vs 2021 (€ 712) Unfavourable step	€ 712 Bank debt 2023: € 712 ▼ 91% vs 2022 (€ 7,712) Favourable step	▼ 91%
Balance sheet total	€ 3,136,248 Balance sheet total 2021: € 3,136,248 First fiscal year in the series	€ 5,256,219 Balance sheet total 2022: € 5,256,219 ▲ 68% vs 2021 (€ 3,136,248) Unchanged	€ 7,486,338 Balance sheet total 2023: € 7,486,338 ▲ 42% vs 2022 (€ 5,256,219) Unchanged	▲ 42%
Employees (FTE)	4.1 Employees (FTE) 2021: 4.1 First fiscal year in the series	12.1 Employees (FTE) 2022: 12.1 ▲ 8 vs 2021 (4.1) Unchanged	8.2 Employees (FTE) 2023: 8.2 ▼ 3.9 vs 2022 (12.1) Unchanged	▼ 3.9

Key figures of UNIZIMA, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.

What happened to UNIZIMA?

What happened at UNIZIMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

UNIZIMA is active according to the CBE. Legal situation: Opening faillissement.

2030 Viva Finance SRL stepped down as director. NBB
2030 Alerion BV stepped down as director. NBB
2026 Hugues BULTOT stepped down as director. NBB
2026 José CASTILLO stepped down as director. NBB
Jul 3, 2024 New annual accounts for financial year 2023: loss of € 3 million. Source: NBB ↗
2024 Viva Finance SRL became a director. NBB
2024 Alerion BV became a director. NBB
Jan 1, 2021 New establishment in Oudergem. KBO

In short

From € 1.9 million loss in 2021 to € 3 million loss in 2023.

Pays suppliers within 127 days on average.

Original PDFs at the National Bank ↗

Management

UNIVERCELLS 100%

The stake of UNIVERCELLS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

UNIZIMA

The shares are held by UNIVERCELLS (100%).

Directors

According to the 2023 annual accounts

Hugues BULTOT

Managing director

Also active at: H ET B MANAGEMENT, UNIVERCELLS, EXOTHERA, Quantoom Biosciences, Quantoom Bioservices, RLM Consulting

since 2020 · until 2026

Viva Finance SRL

Director · represented by Vincent Vanderborght

Also active at: EXOTHERA

since 2024 · until 2030

Alerion BV

Director · represented by David Louvet

Also active at: EXOTHERA, RLM Consulting

since 2024 · until 2030

José CASTILLO

Chairman of the board

Also active at: CER-Groupe, EXOTHERA, Quantoom Biosciences

since 2020 · until 2026

Shareholders

UNIVERCELLS

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Zoning de Jumet,avenue Centrale 52

6040 Charleroi

2.300.608.881

Rue Auguste Piccard 48

6041 Charleroi

Active since 2 March 2020

2.312.642.821

Herrmann-Debrouxlaan 54

1160 Oudergem

Active since 1 January 2021

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

UNIVERCELLS same network

EXOTHERA same network

€ 10 million revenue · 2023

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0744.643.759

VAT number

BE 0744.643.759

Registered office

Zoning de Jumet,avenue Centrale 52, 6040 Charleroi

Names & denominations

UNIZIMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Opening faillissement

Start date

2 March 2020

Peppol

Not registered

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Vervaardiging van overige farmaceutische producten

Vervaardiging van geneesmiddelen

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

UNIZIMA

Warning lights

Financials

What happened to UNIZIMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions